Art. -Nr.: HY-N0256

Hederagenin

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin can also bind to SKP2, with K_D = 67.9 μM. Hederagenin also has preventive potential against alcoholic liver injury.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 465-99-6
Formel: C₃₀H₄₈O₄
Molecular Weight:472.70

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Hederagenin Chemical Structure

CAS. Nr.: 465-99-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[7]

Skp2

Alle COX Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	34.9 μM Compound: He	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
518A2	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 27017553]
8505C	EC₅₀	38 μM Compound: He	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
8505C	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 27017553]
A2780	EC₅₀	19.9 μM Compound: He	Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
A2780	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 27017553]
A2780	EC₅₀	>60 μM Compound: He	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A2780	EC₅₀	>30 μM Compound: He	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A-375	EC₅₀	>60 μM Compound: He	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A549	IC₅₀	>200 μM Compound: 3	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	39 μM Compound: 3	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	38.64 μM Compound: HE	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	EC₅₀	29 μM Compound: He	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
A549	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 27017553]
A549	IC₅₀	10.249 μM Compound: Hederagenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
A549	IC₅₀	>100 μM Compound: alpha-hederagenin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29040953]
A549	IC₅₀	>10 μM Compound: Hederagenin	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
A549	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	[PMID: 31718182]
A549	IC₅₀	>50 μM Compound: He	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 37859723]
A549	IC₅₀	26.23 μM Compound: He	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by Alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by Alamar blue assay	[PMID: 37859723]
AGS	IC₅₀	36.14 μM Compound: alpha-hederagenin	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29040953]
BC	IC₅₀	>5 μg/mL Compound: Hederagenin	Cytotoxicity against human BC cells by colorimetric method Cytotoxicity against human BC cells by colorimetric method	[PMID: 16038539]
BGC-823	IC₅₀	52.07 μM Compound: alpha-hederagenin	Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 29040953]
BT-20	IC₅₀	11.8 μM Compound: He	Cytotoxicity against human BT-20 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay Cytotoxicity against human BT-20 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay	[PMID: 37859723]
DLD-1	IC₅₀	>100 μM Compound: 3	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	>200 μM Compound: 3	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
FaDu	EC₅₀	>60 μM Compound: He	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
FaDu	EC₅₀	>30 μM Compound: He	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HeLa	IC₅₀	42.27 μM Compound: HE	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	53.96 μM Compound: alpha-hederagenin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29040953]
HeLa	IC₅₀	17.42 μg/mL Compound: He	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 37859723]
HepG2	IC₅₀	>20 μM Compound: 15	Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay	[PMID: 21870831]
HepG2	IC₅₀	28.05 μM Compound: HE	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	CC₅₀	>1000 μM Compound: He	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29024910]
HepG2	IC₅₀	35.87 μM Compound: He	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 37859723]
HL-60	IC₅₀	27.52 μM Compound: HE	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HT-29	EC₅₀	50 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
HT-29	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 27017553]
HT-29	EC₅₀	>60 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
HT-29	EC₅₀	>30 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
KB	IC₅₀	>5 μg/mL Compound: Hederagenin	Cytotoxicity against human KB cells by colorimetric method Cytotoxicity against human KB cells by colorimetric method	[PMID: 16038539]
KB	IC₅₀	14.631 μM Compound: Hederagenin	Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
KB	IC₅₀	54.43 μM Compound: alpha-hederagenin	Antiproliferative activity against human KB cells after 72 hrs by MTT assay Antiproliferative activity against human KB cells after 72 hrs by MTT assay	[PMID: 29040953]
KB	IC₅₀	>10 μM Compound: Hederagenin	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
KB	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
LoVo	IC₅₀	1.17 μM Compound: He	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37859723]
LoVo	IC₅₀	1.39 μM Compound: He	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37859723]
M14	IC₅₀	58 μM Compound: 6	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
MCF7	EC₅₀	25.7 μM Compound: He	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
MCF7	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 27017553]
MCF7	IC₅₀	39.389 μM Compound: Hederagenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MCF7	IC₅₀	>10 μM Compound: Hederagenin	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MCF7	EC₅₀	>30 μM Compound: He	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MDA-MB-231	IC₅₀	36.609 μM Compound: Hederagenin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MDA-MB-231	IC₅₀	>10 μM Compound: Hederagenin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MDA-MB-231	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MKN-45	IC₅₀	53.69 μM Compound: alpha-hederagenin	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 29040953]
NCI-H187	IC₅₀	>5 μg/mL Compound: Hederagenin	Cytotoxicity against human NCI-H187 cells by colorimetric method Cytotoxicity against human NCI-H187 cells by colorimetric method	[PMID: 16038539]
NCI-H1975	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	>10 μM Compound: Hederagenin	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NIH3T3	EC₅₀	>30 μM Compound: He; Hederagenin	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 27017553]
NIH3T3	EC₅₀	>30 μM Compound: He	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
Sf9	IC₅₀	>20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	>20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
Sf9	IC₅₀	>20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
SW-1736	EC₅₀	>60 μM Compound: He	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
SW-1736	EC₅₀	>30 μM Compound: He	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
U-87MG ATCC	IC₅₀	35.95 μM Compound: HE	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]

In Vitro

Hederagenin (1 μM, 2 μM; 48 h) disrupts mitochondrial membrane potential, increases intracellular reactive oxygen species (ROS) content, and has a cytotoxic effect on cancer cells^[4].
Hederagenin (1 μM, 2 μM; 48 h) induces apoptosis in human colon cancer LoVo cells, upregulates apoptosis-related proteins (Bax), and reduces apoptosis inhibitory proteins (Bcl-2, Bcl-xL, and Survivin) levels^[4].
Hederagenin (50 μM; 4 h) also blocks autophagic flux-induced ROS accumulation and enhances the cytotoxicity of Cisplatin and Paclitaxel in lung cancer cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Hederagenin (25 mg/kg; po; 11 d) alone did not affect tumor growth in NCI-H1299 xenograft mice. However, it has a synergistic effect with Cisplatin (1 mg/kg) to inhibit tumor growth^[4].
Hederagenin (50 mg/kg; po; once daily for 21 days) exerts anti-inflammatory and anti-apoptotic activities and reduces liver damage induced by 25% ethanol in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 465-99-6
Appearance Solid
Molecular Weight 472.70
Formel C₃₀H₄₈O₄
Color White to off-white
SMILES

CC1(C)CC[C@@](CC[C@]2(C)C3=CC[C@@]4([H])[C@@]2(C)CC[C@]5([H])[C@]4(C)CC[C@H](O)[C@]5(CO)C)(C(O)=O)[C@@]3([H])C1
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All Cell Proliferation/Viability AssayCell Imaging/StainingApoptosis AnalysisWBRT-PCR

Sort by:

Journal Impact Factor

J Agric Food Chem

Distinctive Behavior and Selective Modulation of PPARγ by Pentacyclic Triterpenoid Pomolic Acid and Hederagenin from Rosa canina. [Abstract]

2026 May 13;74(18):14376-14392. PMID: 42057314
CNS Neurosci Ther

ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway. [Abstract]

2026 Mar;32(3):e70814. PMID: 41795136
Bone Joint Res

Hederagenin promotes SIRT6 to attenuate epidural scar formation by aggravating PRMT1 deacetylation. [Abstract]

2025 Jun 13;14(6):516-526. PMID: 40511498

Hederagenin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Jun 13;14(6):516-526. [Abstract]

Cell Counting Kit (CCK)-8 method was performed to evaluate cell viability treated with Hederagenin (1, 5, 10, 20, 40, 80, 100 μM, 6, 12, 24, 48, 72 h).

Hederagenin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Jun 13;14(6):516-526. [Abstract]

Apoptosis rate of fibroblasts was measured using flow cytometry treated with Hederageni (HE) (20, 40 μM).

Hederagenin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Jun 13;14(6):516-526. [Abstract]

The expressions of target proteins were evaluated by western blotting treated withHederagenin (HE) (20, 40 μM).

Hederagenin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Jun 13;14(6):516-526. [Abstract]

Hederagenin (HE) (20, 40 μM) treatment increased SIRT6 mRNA expression in a dose-dependent manner in fibroblasts with or without TGF-β1 stimulation by RT-qPCR.
J Proteome Res

Elucidating the Molecular Mechanisms of Hederagenin-Regulated Mitophagy in Cervical Cancer SiHa Cells through an Integrative Approach Combining Proteomics and Advanced Network Association Algorithm. [Abstract]

2025 Mar 26. PMID: 40135937

Hederagenin purchased from MedChemExpress. Usage Cited in: J Proteome Res. 2025 Mar 26. [Abstract]

SiHa and ECT1/E6E7 for TUNEL/DAPI staining treated with Hederagenin (Hed).
Biochem Biophys Res Commun

Hederagenin promotes lung cancer cell death by activating CHAC1-dependent ferroptosis pathway. [Abstract]

2024 May 8:718:150085. PMID: 38735142
Biol Pharm Bull

He-Wei-Decoction Ameliorates Chronic Atrophic Gastritis via Modulation of the TLR4/NF-κB Signaling Pathway. [Abstract]

2025;48(10):1514-1525. PMID: 41083380
Ann Med Surg (Lond)

Network pharmacology prediction and experiment validation of anti-liver cancer activity of Curcumae Rhizoma and Hedyotis diffusa Willd. [Abstract]

2024 Apr 23;86(6):3337-3348. PMID: 38846818
Bioengineered

The protective effect of hederagenin on renal fibrosis by targeting muscarinic acetylcholine receptor. [Abstract]

2022 Apr;13(4):8689-8698. PMID: 35322725

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (105.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1155 mL

10.5775 mL

21.1551 mL

5 mM

0.4231 mL

2.1155 mL

4.2310 mL

10 mM

0.2116 mL

1.0578 mL

2.1155 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. Evid Based Complement Alternat Med, 2015, Oct 19 [Content Brief]

[2]. Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem, 2015 Nov 13, 105:57-62 [Content Brief]

[3]. Chul Won Lee et al. Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. Int Immunopharmacol, 2015 Dec, 29(2):528-37. [Content Brief]

[4]. Liu BX, et al. Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway. BMC Complement Altern Med. 2014 Oct 24;14:412. [Content Brief]

[5]. Kim GJ, et al. Hederagenin Supplementation Alleviates the Pro-Inflammatory and Apoptotic Response to Alcohol in Rats. Nutrients. 2017 Jan 6;9(1):41. [Content Brief]

[6]. Wang K, et al. Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells. Cell Death Dis. 2020 Aug 13;11(8):611. [Content Brief]

[7]. Chen L, et al. Natural Product-Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2. J Med Chem. 2026;69(4):4579-4601. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1155 mL	10.5775 mL	21.1551 mL	52.8877 mL
	5 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	10 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	15 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	20 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	25 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	30 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	40 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	50 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL
	60 mM	0.0353 mL	0.1763 mL	0.3526 mL	0.8815 mL
	80 mM	0.0264 mL	0.1322 mL	0.2644 mL	0.6611 mL
	100 mM	0.0212 mL	0.1058 mL	0.2116 mL	0.5289 mL

Keywords

Hederagenin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hederagenin

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Amino Acid Metabolism Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hederagenin

Alle COX Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hederagenin Related Classifications

HY-N0256 Related Classifications